<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Boehringer Ingelheim</title>
	<atom:link href="http://www.tapanray.in/tag/boehringer-ingelheim/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Biosimilar Drugs: First Indian Foot Print In An Uncharted Frontier</title>
		<link>http://www.tapanray.in/biosimilar-drugs-first-indian-foot-print-in-an-uncharted-frontier/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=biosimilar-drugs-first-indian-foot-print-in-an-uncharted-frontier</link>
		<comments>http://www.tapanray.in/biosimilar-drugs-first-indian-foot-print-in-an-uncharted-frontier/#comments</comments>
		<pubDate>Mon, 04 Apr 2016 00:00:51 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Barriers]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[Boehringer Ingelheim]]></category>
		<category><![CDATA[Challenging]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[doctor]]></category>
		<category><![CDATA[drivers]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Eli Lilly]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[frontier]]></category>
		<category><![CDATA[Glargine]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[insulin]]></category>
		<category><![CDATA[Interchangeability]]></category>
		<category><![CDATA[Japan]]></category>
		<category><![CDATA[label]]></category>
		<category><![CDATA[Lantus]]></category>
		<category><![CDATA[lantus XR]]></category>
		<category><![CDATA[name]]></category>
		<category><![CDATA[non-proprietory]]></category>
		<category><![CDATA[opportunity]]></category>
		<category><![CDATA[original. substitution]]></category>
		<category><![CDATA[pen]]></category>
		<category><![CDATA[pre-filled]]></category>
		<category><![CDATA[prescriber]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[skepticism]]></category>
		<category><![CDATA[states]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Toujeo]]></category>
		<category><![CDATA[uncharted]]></category>
		<category><![CDATA[United]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7578</guid>
		<description><![CDATA[A homegrown Indian biologic manufacturer is now about to leave behind its first foot-print, with a ‘made in India’ biosimilar drug, in one of the largest pharma market of the world. This was indeed an uncharted frontier, and a dream &#8230; <a href="http://www.tapanray.in/biosimilar-drugs-first-indian-foot-print-in-an-uncharted-frontier/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/biosimilar-drugs-first-indian-foot-print-in-an-uncharted-frontier/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Digital Marketing: Is Pharma Still A Laggard?</title>
		<link>http://www.tapanray.in/digital-marketing-is-pharma-still-a-laggard/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=digital-marketing-is-pharma-still-a-laggard</link>
		<comments>http://www.tapanray.in/digital-marketing-is-pharma-still-a-laggard/#comments</comments>
		<pubDate>Mon, 17 Aug 2015 00:00:16 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[Boehringer Ingelheim]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[Cephalon]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[Freebies]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[laggard]]></category>
		<category><![CDATA[Maggi]]></category>
		<category><![CDATA[Maggie]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[Nestle]]></category>
		<category><![CDATA[nexium]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Salford Business School]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCB]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6946</guid>
		<description><![CDATA[‘Brand Marketing’ in the pharmaceutical industry, across the world, has mostly remained tradition bound, despite its rapid embracement of modern state of the art tools and technology in most other areas of the business. Many other industries have been demonstrating &#8230; <a href="http://www.tapanray.in/digital-marketing-is-pharma-still-a-laggard/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/digital-marketing-is-pharma-still-a-laggard/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Quantum Value Addition With Health Apps, Going Beyond Drugs</title>
		<link>http://www.tapanray.in/quantum-value-addition-with-health-apps-going-beyond-drugs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=quantum-value-addition-with-health-apps-going-beyond-drugs</link>
		<comments>http://www.tapanray.in/quantum-value-addition-with-health-apps-going-beyond-drugs/#comments</comments>
		<pubDate>Mon, 30 Mar 2015 00:00:58 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[Betaseron]]></category>
		<category><![CDATA[beyond]]></category>
		<category><![CDATA[BMI]]></category>
		<category><![CDATA[Boehringer Ingelheim]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[fitness]]></category>
		<category><![CDATA[hardware]]></category>
		<category><![CDATA[Health Apps]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[it]]></category>
		<category><![CDATA[mApps]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[myBETAapp]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Podhaler Pro]]></category>
		<category><![CDATA[Pradaxa Health App]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[software]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[tracker]]></category>
		<category><![CDATA[Xarelto Patient Care App]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6475</guid>
		<description><![CDATA[Besides all important brand attributes and how well those are communicated to the doctors, the &#8216;game winning&#8217; differentiating factors in the prescription drug business, as it appears today, would revolve around overall quality of patient-centric approach and offerings of pharma &#8230; <a href="http://www.tapanray.in/quantum-value-addition-with-health-apps-going-beyond-drugs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/quantum-value-addition-with-health-apps-going-beyond-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
